20.80

1.98% -0.42

Pre-market: 20.85 0.05 +0.24%

Genmab Adr (GMAB)

Overview News Price History Option Chain Why GMAB Down? Discussions Forecast Stock Split

Genmab Adr stock is traded at $20.80, with a volume of 1.10M. It is down -1.98% in the last 24 hours and up +3.84% over the past month. Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Previous Close:

$21.22

Open:

$20.85

24h Volume:

1.10M

Relative Volume:

0.87

Market Cap:

$13.21B

Revenue:

$2.89B

Net Income/Loss:

$684.26M

P/E Ratio:

19.76

EPS:

1.0524

Net Cash Flow:

$958.82M

1W Performance:

-6.09%

1M Performance:

+3.84%

6M Performance:

-22.47%

1Y Performance:

-28.64%

1-Day Range:

$20.75

$21.02

1-Week Range:

$19.89

$22.08

52-Week Range:

$19.85

$31.88

Genmab Adr Stock (GMAB) Company Profile

Name

Genmab Adr

Sector

Healthcare (1172)

Industry

Biotechnology (684)

Phone

Address

Employee

2,635

Twitter

@Genmab

Next Earnings Date

2024-11-06

Latest SEC Filings

GMAB's Discussions on Twitter

Compare GMAB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GMAB Genmab Adr	20.80	13.21B	2.89B	684.26M	958.82M	1.0524
VRTX Vertex Pharmaceuticals Inc	422.00	108.68B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	681.58	74.90B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	640.52	38.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.27	31.76B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	111.93	26.83B	3.30B	-501.07M	1.03B	-2.1146

Genmab Adr Stock (GMAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-08-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Resumed	Morgan Stanley	Equal-Weight
Aug-20-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-15-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-23-24	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-22-24	Downgrade	Citigroup	Neutral → Sell
Dec-06-23	Upgrade	UBS	Neutral → Buy
Nov-10-23	Upgrade	Deutsche Bank	Hold → Buy
Nov-08-23	Upgrade	DNB Markets	Sell → Buy
Oct-18-23	Initiated	Exane BNP Paribas	Underperform
Sep-06-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-24-23	Initiated	BTIG Research	Buy
Jul-14-23	Initiated	HSBC Securities	Buy
May-31-23	Initiated	UBS	Neutral
May-12-23	Initiated	Morgan Stanley	Underweight
Dec-20-22	Downgrade	Citigroup	Buy → Neutral
Nov-14-22	Initiated	William Blair	Mkt Perform
Nov-11-22	Downgrade	Deutsche Bank	Buy → Hold
Jun-24-22	Initiated	BMO Capital Markets	Market Perform
May-02-22	Initiated	Cowen	Market Perform
Mar-16-22	Upgrade	UBS	Neutral → Buy
Jan-31-22	Upgrade	H.C. Wainwright	Neutral → Buy
Jan-03-22	Downgrade	Guggenheim	Buy → Neutral
Dec-01-21	Initiated	Berenberg	Sell
Sep-16-21	Downgrade	Jefferies	Buy → Hold
Sep-07-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Aug-24-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-20-21	Initiated	Deutsche Bank	Buy
Jan-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-20	Downgrade	Bryan Garnier	Neutral → Sell
Sep-08-20	Initiated	SVB Leerink	Mkt Perform
Jun-25-20	Downgrade	Credit Suisse	Outperform → Neutral
Apr-23-20	Initiated	Credit Suisse	Outperform
Feb-24-20	Reiterated	H.C. Wainwright	Buy
Jan-13-20	Initiated	SunTrust	Buy
Dec-12-19	Downgrade	Deutsche Bank	Buy → Hold
Sep-13-19	Upgrade	BofA/Merrill	Neutral → Buy
Sep-12-19	Upgrade	JP Morgan	Neutral → Overweight
Aug-12-19	Initiated	Guggenheim	Buy
Aug-12-19	Initiated	Morgan Stanley	Overweight
Aug-12-19	Initiated	RBC Capital Mkts	Outperform